Pegfilgrastim Biosimilars Market Report 2026
Download Free Sample Buy Now
Pegfilgrastim Biosimilars Market Global Report 2026 Market Report Infographic Image

Published : February 2026

Pages : 250

Format : PDF

Delivery Time : 2-3 Business Days

Report Price : $4490.00

Pegfilgrastim Biosimilars Market Report 2026

Global Outlook – By Application (Chemotherapy Treatment, Transplantation, Other Applications), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Mail-Order Pharmacies ), By Route of Administration (Prefilled Syringes (PFS), On-body Injectors (OBI), Other Routes) - Market Size, Trends, And Global Forecast 2025-2034

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
Purchase This Report Download Sample PDF
Item added to cart!

Pegfilgrastim Biosimilars Market Overview

• Pegfilgrastim Biosimilars market size has reached to $1.92 billion in 2025

• Expected to grow to $2.65 billion in 2030 at a compound annual growth rate (CAGR) of 6.7%

• Growth Driver: Government Initiatives Drive Growth In Pegfilgrastim Biosimilars Market

• Market Trend: High Quality Biosimilar For Providing Better Alternative

• North America was the largest region in 2025 and Middle East is the fastest growing region.

What Is Covered Under Pegfilgrastim Biosimilars Market?

Pegfilgrastim biosimilars refer to a biosimilar that is intended to be used in conjunction with supportive care for people with non-myeloid cancer. It can help prevent or treat infections brought on by myelosuppressive chemotherapy by promoting the formation of certain white blood cells.

The different applications of pegfilgrastim biosimilars are chemotherapy treatment, transplantation, and others. Chemotherapy is a cancer treatment that involves the administration of one or more anti-cancer medications as part of a defined protocol. The various distribution channels include hospital pharmacies, retail pharmacies, and mail-order pharmacies.

Pegfilgrastim Biosimilars Market Global Report 2026 Market Report bar graph

What Is The Pegfilgrastim Biosimilars Market Size and Share 2026?

The pegfilgrastim biosimilars market size has grown strongly in recent years. It will grow from $1.92 billion in 2025 to $2.04 billion in 2026 at a compound annual growth rate (CAGR) of 6.3%. The growth in the historic period can be attributed to high cost of originator pegfilgrastim, limited availability of biosimilars, growing cancer patient population, increasing chemotherapy procedures, rising awareness of neutropenia management.

What Is The Pegfilgrastim Biosimilars Market Growth Forecast?

The pegfilgrastim biosimilars market size is expected to see strong growth in the next few years. It will grow to $2.65 billion in 2030 at a compound annual growth rate (CAGR) of 6.7%. The growth in the forecast period can be attributed to launch of new biosimilars, increasing adoption in supportive oncology care, expansion of hospital and retail pharmacy networks, government incentives for biosimilar usage, rising investments in stem cell transplantation therapies. Major trends in the forecast period include rising adoption of pegfilgrastim biosimilars in supportive cancer care, expansion of hospital and retail pharmacy distribution channels, increasing focus on reducing chemotherapy-induced neutropenia, growth in hematopoietic and peripheral blood stem cell transplantation applications, rising investments in treatment of chronic and severe congenital neutropenia.

Customer representative image Book your 30 minutes free consultation with our research experts
Contact Us

Global Pegfilgrastim Biosimilars Market Segmentation

1) By Application: Chemotherapy Treatment, Transplantation, Other Applications

2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Mail-Order Pharmacies

3) By Route of Administration: Prefilled Syringes (PFS), On-body Injectors (OBI), Other Routes

Subsegments:

1) By Chemotherapy Treatment: Supportive Care for Cancer Patients, Reduction of Chemotherapy-Induced Neutropenia

2) By Transplantation: Hematopoietic Stem Cell Transplantation, Peripheral Blood Stem Cell Transplantation

3) By Other Applications: Treatment of Chronic Neutropenia, Treatment of Severe Congenital Neutropenia

What Are The Drivers Of The Pegfilgrastim Biosimilars Market?

Government initiatives for the development of biosimilars are expected to drive the pegfilgrastim biosimilars market. Governments worldwide are focusing on the development of biosimilars due to their cost-effective nature. The US Food and Drug Administration (FDA) launched a Biosimilar Action Plan, to increase treatment options. The Australian government is committed to the Biosimilar Awareness Initiative, and they improved their commitment by supporting the Generic and Biosimilar Medicines Association through a grant of $5 million to accept increased general biosimilar education and activities that promote the suitable dispensing, prescription, and use of biosimilar medicines. Hence, the government initiatives for the development of biosimilars aid in the increased production and awareness that, in turn, support the growth of the pegfilgrastim biosimilars industry.

The increased incidence of cancer is expected to propel the pegfilgrastim biosimilars market going forward. Cancer refers to a group of diseases characterized by the uncontrolled growth and spread of abnormal cells. The increasing cancer prevalence is due to aging population, as advanced age is the most significant risk factor for developing most types of cancer, with the majority of cases occurring in individuals over 65 years old. Pegfilgrastim biosimilars are used to reduce the risk of infection in cancer patients undergoing chemotherapy by stimulating white blood cell production. For instance, in October 2025, according to National Health Service (NHS), a UK-based government health agency, there were 354,820 new cancer diagnoses in 2023, an average of 972 per day, which is 8,605 more than in 2022. Therefore, the increased incidence of cancer is driving the pegfilgrastim biosimilars industry.

Key Players In The Global Pegfilgrastim Biosimilars Market

Major companies operating in the pegfilgrastim biosimilars market are Amgen, Mylan N.V., Sandoz (a Novartis division), Teva Pharmaceutical Industries Ltd., Biocon, Pfizer, Celltrion Healthcare, Coherus BioSciences, Gedeon Richter, Fresenius Kabi, Hetero Labs, Intas Pharmaceuticals, LG Chem, Merck KGaA, Zydus Cadila, Aurobindo Pharma, Apotex Inc., Dr. Reddy's Laboratories, Stada Arzneimittel AG, Shanghai Henlius Biotech, Alvotech, EirGenix, Kye Pharmaceuticals, CinnaGen, Boryung Pharmaceutical, Sinopharm

Global Pegfilgrastim Biosimilars Market Trends and Insights

Major companies operating in the pegfilgrastim biosimilars market are focusing on technological innovation in biopharmaceuticals, such as high-quality biosimilars to provide safe, effective, and accessible alternatives to original biologic therapies for cancer patients. High-quality biosimilars refer to biologic drugs that closely match the reference product in structure, function, safety, and efficacy. For instance, in February 2023, Fresenius Kabi, a Germany-based healthcare company specializing in pharmaceuticals and medical technologies, launched Stimufend, its first pegfilgrastim biosimilar in the U.S. Stimufend prevents and treats chemotherapy-induced neutropenia and comes as a 6 mg/0.6 mL solution in a single-use pre-filled syringe with a built-in needle guard. By combining advanced biosimilar development and user-friendly delivery, Stimufend represents a technological advancement in making high-quality biologic therapies more accessible.

Need data on a specific region in this market?
Request Regional Data

What Are Latest Mergers And Acquisitions In The Pegfilgrastim Biosimilars Market?

In August 2025, Intas Pharmaceuticals Ltd., an India-based biotechnology company, acquired the UDENYCA from Coherus BioSciences, Inc. for an undisclosed amount. With this acquisition, Intas Pharmaceuticals and Accord BioPharma aim to strengthen their position as a global leader in pegfilgrastim, expand their FDA-approved biosimilar portfolio, and enhance patient access to high-quality, flexible treatment options for reducing the risk of infection in cancer patients. Coherus BioSciences Inc. is a US-based, commercial-stage biopharmaceutical company, focused on both biosimilars and innovative immuno-oncology therapies, with a team of industry veterans leveraging deep expertise in biologics development and commercialization.

Regional Insights

North America was the largest region in the pegfilgrastim biosimilars market in 2025. Middle East is expected to be the fastest growing region in the global pegfilgrastim biosimilars market share during the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Pegfilgrastim Biosimilars Market?

The pegfilgrastim biosimilars market consists of sales of fulphila, pelgraz, pelmeg, udenyca, ziextenzo, grasustek, fylnetra, and stimufend. Values in this market are ""factory gate values,"" that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Pegfilgrastim Biosimilars Market Report 2026?

The pegfilgrastim biosimilars market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the pegfilgrastim biosimilars industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.

Author : Abhilash Pyata

Pegfilgrastim Biosimilars Market Report Forecast Analysis

Report AttributeDetails
Market Size Value In 2026 $2.04 billion
Revenue Forecast In 2035 $2.65 billion
Growth Rate CAGR of 6.3% from 2026 to 2035
Base Year For Estimation 2025
Actual Estimates/Historical Data 2020-2025
Forecast Period 2026 - 2030 - 2035
Market Representation Revenue in USD Billion and CAGR from 2026 to 2035
Segments Covered Application, Distribution Channel, Route of Administration
Regional Scope Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Country Scope The countries covered in the report are Australia, Brazil, China, France, Germany, India, ...
Key Companies Profiled Amgen, Mylan N.V., Sandoz (a Novartis division), Teva Pharmaceutical Industries Ltd., Biocon, Pfizer, Celltrion Healthcare, Coherus BioSciences, Gedeon Richter, Fresenius Kabi, Hetero Labs, Intas Pharmaceuticals, LG Chem, Merck KGaA, Zydus Cadila, Aurobi
Customization ScopeRequest for Customization
Pricing And Purchase OptionsExplore Purchase Options

Table Of Contents

1. Executive Summary

1.1. Key Market Insights (2020-2035)

1.2. Visual Dashboard: Market Size, Growth Rate, Hotspots

1.3. Major Factors Driving the Market

1.4. Top Three Trends Shaping the Market

2. Pegfilgrastim Biosimilars Market Characteristics

2.1. Market Definition & Scope

2.2. Market Segmentations

2.3. Overview of Key Products and Services

2.4. Global Pegfilgrastim Biosimilars Market Attractiveness Scoring And Analysis

2.4.1. Overview of Market Attractiveness Framework

2.4.2. Quantitative Scoring Methodology

2.4.3. Factor-Wise Evaluation

Growth Potential Analysis, Competitive Dynamics Assessment, Strategic Fit Assessment And Risk Profile Evaluation

2.4.4. Market Attractiveness Scoring and Interpretation

2.4.5. Strategic Implications and Recommendations

3. Pegfilgrastim Biosimilars Market Supply Chain Analysis

3.1. Overview of the Supply Chain and Ecosystem

3.2. List Of Key Raw Materials, Resources & Suppliers

3.3. List Of Major Distributors and Channel Partners

3.4. List Of Major End Users

4. Global Pegfilgrastim Biosimilars Market Trends And Strategies

4.1. Key Technologies & Future Trends

4.1.1 Biotechnology, Genomics & Precision Medicine

4.1.2 Digitalization, Cloud, Big Data & Cybersecurity

4.1.3 Industry 4.0 & Intelligent Manufacturing

4.1.4 Artificial Intelligence & Autonomous Intelligence

4.1.5 Internet Of Things (Iot), Smart Infrastructure & Connected Ecosystems

4.2. Major Trends

4.2.1 Rising Adoption Of Pegfilgrastim Biosimilars In Supportive Cancer Care

4.2.2 Expansion Of Hospital And Retail Pharmacy Distribution Channels

4.2.3 Increasing Focus On Reducing Chemotherapy-Induced Neutropenia

4.2.4 Growth In Hematopoietic And Peripheral Blood Stem Cell Transplantation Applications

4.2.5 Rising Investments In Treatment Of Chronic And Severe Congenital Neutropenia

5. Pegfilgrastim Biosimilars Market Analysis Of End Use Industries

5.1 Hospitals

5.2 Retail Pharmacies

5.3 Mail-Order Pharmacies

5.4 Oncology Centers

5.5 Cancer Treatment Clinics

6. Pegfilgrastim Biosimilars Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, Supply Chain Impact from Tariff War & Trade Protectionism, And Covid And Recovery On The Market

7. Global Pegfilgrastim Biosimilars Strategic Analysis Framework, Current Market Size, Market Comparisons And Growth Rate Analysis

7.1. Global Pegfilgrastim Biosimilars PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)

7.2. Global Pegfilgrastim Biosimilars Market Size, Comparisons And Growth Rate Analysis

7.3. Global Pegfilgrastim Biosimilars Historic Market Size and Growth, 2020 - 2025, Value ($ Billion)

7.4. Global Pegfilgrastim Biosimilars Forecast Market Size and Growth, 2025 - 2030, 2035F, Value ($ Billion)

8. Global Pegfilgrastim Biosimilars Total Addressable Market (TAM) Analysis for the Market

8.1. Definition and Scope of Total Addressable Market (TAM)

8.2. Methodology and Assumptions

8.3. Global Total Addressable Market (TAM) Estimation

8.4. TAM vs. Current Market Size Analysis

8.5. Strategic Insights and Growth Opportunities from TAM Analysis

9. Pegfilgrastim Biosimilars Market Segmentation

9.1. Global Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Chemotherapy Treatment, Transplantation, Other Applications

9.2. Global Pegfilgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Hospital Pharmacies, Retail Pharmacies, Mail-Order Pharmacies

9.3. Global Pegfilgrastim Biosimilars Market, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Prefilled Syringes (PFS), On-body Injectors (OBI), Other Routes

9.4. Global Pegfilgrastim Biosimilars Market, Sub-Segmentation Of Chemotherapy Treatment, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Supportive Care for Cancer Patients, Reduction of Chemotherapy-Induced Neutropenia

9.5. Global Pegfilgrastim Biosimilars Market, Sub-Segmentation Of Transplantation, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Hematopoietic Stem Cell Transplantation, Peripheral Blood Stem Cell Transplantation

9.6. Global Pegfilgrastim Biosimilars Market, Sub-Segmentation Of Other Applications, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Treatment of Chronic Neutropenia, Treatment of Severe Congenital Neutropenia

10. Pegfilgrastim Biosimilars Market Regional And Country Analysis

10.1. Global Pegfilgrastim Biosimilars Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

10.2. Global Pegfilgrastim Biosimilars Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

11. Asia-Pacific Pegfilgrastim Biosimilars Market

11.1. Asia-Pacific Pegfilgrastim Biosimilars Market Overview

Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

11.2. Asia-Pacific Pegfilgrastim Biosimilars Market, Segmentation By Application, Segmentation By Distribution Channel, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

12. China Pegfilgrastim Biosimilars Market

12.1. China Pegfilgrastim Biosimilars Market Overview

Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

12.2. China Pegfilgrastim Biosimilars Market, Segmentation By Application, Segmentation By Distribution Channel, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

13. India Pegfilgrastim Biosimilars Market

13.1. India Pegfilgrastim Biosimilars Market, Segmentation By Application, Segmentation By Distribution Channel, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

14. Japan Pegfilgrastim Biosimilars Market

14.1. Japan Pegfilgrastim Biosimilars Market Overview

Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

14.2. Japan Pegfilgrastim Biosimilars Market, Segmentation By Application, Segmentation By Distribution Channel, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

15. Australia Pegfilgrastim Biosimilars Market

15.1. Australia Pegfilgrastim Biosimilars Market, Segmentation By Application, Segmentation By Distribution Channel, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

16. Indonesia Pegfilgrastim Biosimilars Market

16.1. Indonesia Pegfilgrastim Biosimilars Market, Segmentation By Application, Segmentation By Distribution Channel, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

17. South Korea Pegfilgrastim Biosimilars Market

17.1. South Korea Pegfilgrastim Biosimilars Market Overview

Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

17.2. South Korea Pegfilgrastim Biosimilars Market, Segmentation By Application, Segmentation By Distribution Channel, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

18. Taiwan Pegfilgrastim Biosimilars Market

18.1. Taiwan Pegfilgrastim Biosimilars Market Overview

Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

18.2. Taiwan Pegfilgrastim Biosimilars Market, Segmentation By Application, Segmentation By Distribution Channel, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

19. South East Asia Pegfilgrastim Biosimilars Market

19.1. South East Asia Pegfilgrastim Biosimilars Market Overview

Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

19.2. South East Asia Pegfilgrastim Biosimilars Market, Segmentation By Application, Segmentation By Distribution Channel, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

20. Western Europe Pegfilgrastim Biosimilars Market

20.1. Western Europe Pegfilgrastim Biosimilars Market Overview

Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

20.2. Western Europe Pegfilgrastim Biosimilars Market, Segmentation By Application, Segmentation By Distribution Channel, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

21. UK Pegfilgrastim Biosimilars Market

21.1. UK Pegfilgrastim Biosimilars Market, Segmentation By Application, Segmentation By Distribution Channel, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

22. Germany Pegfilgrastim Biosimilars Market

22.1. Germany Pegfilgrastim Biosimilars Market, Segmentation By Application, Segmentation By Distribution Channel, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

23. France Pegfilgrastim Biosimilars Market

23.1. France Pegfilgrastim Biosimilars Market, Segmentation By Application, Segmentation By Distribution Channel, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

24. Italy Pegfilgrastim Biosimilars Market

24.1. Italy Pegfilgrastim Biosimilars Market, Segmentation By Application, Segmentation By Distribution Channel, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

25. Spain Pegfilgrastim Biosimilars Market

25.1. Spain Pegfilgrastim Biosimilars Market, Segmentation By Application, Segmentation By Distribution Channel, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

26. Eastern Europe Pegfilgrastim Biosimilars Market

26.1. Eastern Europe Pegfilgrastim Biosimilars Market Overview

Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

26.2. Eastern Europe Pegfilgrastim Biosimilars Market, Segmentation By Application, Segmentation By Distribution Channel, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

27. Russia Pegfilgrastim Biosimilars Market

27.1. Russia Pegfilgrastim Biosimilars Market, Segmentation By Application, Segmentation By Distribution Channel, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

28. North America Pegfilgrastim Biosimilars Market

28.1. North America Pegfilgrastim Biosimilars Market Overview

Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

28.2. North America Pegfilgrastim Biosimilars Market, Segmentation By Application, Segmentation By Distribution Channel, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

29. USA Pegfilgrastim Biosimilars Market

29.1. USA Pegfilgrastim Biosimilars Market Overview

Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

29.2. USA Pegfilgrastim Biosimilars Market, Segmentation By Application, Segmentation By Distribution Channel, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

30. Canada Pegfilgrastim Biosimilars Market

30.1. Canada Pegfilgrastim Biosimilars Market Overview

Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

30.2. Canada Pegfilgrastim Biosimilars Market, Segmentation By Application, Segmentation By Distribution Channel, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

31. South America Pegfilgrastim Biosimilars Market

31.1. South America Pegfilgrastim Biosimilars Market Overview

Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

31.2. South America Pegfilgrastim Biosimilars Market, Segmentation By Application, Segmentation By Distribution Channel, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

32. Brazil Pegfilgrastim Biosimilars Market

32.1. Brazil Pegfilgrastim Biosimilars Market, Segmentation By Application, Segmentation By Distribution Channel, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

33. Middle East Pegfilgrastim Biosimilars Market

33.1. Middle East Pegfilgrastim Biosimilars Market Overview

Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

33.2. Middle East Pegfilgrastim Biosimilars Market, Segmentation By Application, Segmentation By Distribution Channel, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

34. Africa Pegfilgrastim Biosimilars Market

34.1. Africa Pegfilgrastim Biosimilars Market Overview

Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

34.2. Africa Pegfilgrastim Biosimilars Market, Segmentation By Application, Segmentation By Distribution Channel, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

35. Pegfilgrastim Biosimilars Market Regulatory and Investment Landscape

36. Pegfilgrastim Biosimilars Market Competitive Landscape And Company Profiles

36.1. Pegfilgrastim Biosimilars Market Competitive Landscape And Market Share 2024

36.1.1. Top 10 Companies (Ranked by revenue/share)

36.2. Pegfilgrastim Biosimilars Market - Company Scoring Matrix

36.2.1. Market Revenues

36.2.2. Product Innovation Score

36.2.3. Brand Recognition

36.3. Pegfilgrastim Biosimilars Market Company Profiles

36.3.1. Amgen Overview, Products and Services, Strategy and Financial Analysis

36.3.2. Mylan N.V. Overview, Products and Services, Strategy and Financial Analysis

36.3.3. Sandoz (a Novartis division) Overview, Products and Services, Strategy and Financial Analysis

36.3.4. Teva Pharmaceutical Industries Ltd. Overview, Products and Services, Strategy and Financial Analysis

36.3.5. Biocon Overview, Products and Services, Strategy and Financial Analysis

37. Pegfilgrastim Biosimilars Market Other Major And Innovative Companies

Pfizer, Celltrion Healthcare, Coherus BioSciences, Gedeon Richter, Fresenius Kabi, Hetero Labs, Intas Pharmaceuticals, LG Chem, Merck KGaA, Zydus Cadila, Aurobindo Pharma, Apotex Inc., Dr. Reddy's Laboratories, Stada Arzneimittel AG, Shanghai Henlius Biotech

38. Global Pegfilgrastim Biosimilars Market Competitive Benchmarking And Dashboard

39. Key Mergers And Acquisitions In The Pegfilgrastim Biosimilars Market

40. Pegfilgrastim Biosimilars Market High Potential Countries, Segments and Strategies

40.1 Pegfilgrastim Biosimilars Market In 2030 - Countries Offering Most New Opportunities

40.2 Pegfilgrastim Biosimilars Market In 2030 - Segments Offering Most New Opportunities

40.3 Pegfilgrastim Biosimilars Market In 2030 - Growth Strategies

40.3.1 Market Trend Based Strategies

40.3.2 Competitor Strategies

41. Appendix

41.1. Abbreviations

41.2. Currencies

41.3. Historic And Forecast Inflation Rates

41.4. Research Inquiries

41.5. The Business Research Company

41.6. Copyright And Disclaimer

List Of Tables

    Table 1: Global Pegfilgrastim Biosimilars Market, Overview Of Key Products - Product Examples
  • Table 2: Global Pegfilgrastim Biosimilars Market Attractiveness, Factor-Wise Evaluation
  • Table 3: Global Pegfilgrastim Biosimilars Market, Supply Chain Analysis
  • Table 4: Global Pegfilgrastim Biosimilars Market, Major Raw Material Providers
  • Table 5: Global Pegfilgrastim Biosimilars Market, Major Resource Providers
  • Table 6: Global Pegfilgrastim Biosimilars Market, Major Manufacturers (Suppliers)
  • Table 7: Global Pegfilgrastim Biosimilars Market, Major Distributors And Channel Partners
  • Table 8: Global Pegfilgrastim Biosimilars Market, Key Technologies & Future Trends
  • Table 9: Global Pegfilgrastim Biosimilars Market, Major Trends
  • Table 10: Global Pegfilgrastim Biosimilars Market, Major End Users
  • Table 11: Global Pegfilgrastim Biosimilars Market, PESTEL (Political, Economic, Social, Technology, Environmental and Legal) Analysis
  • Table 12: Global Pegfilgrastim Biosimilars Historic Market Growth, 2020-2025, $ Billion
  • Table 13: Global Pegfilgrastim Biosimilars Forecast Market Growth, 2025-2030F, 2035F, $ Billion
  • Table 14: Global Pegfilgrastim Biosimilars Market - TAM, US$ Billion, 2025
  • Table 15: Global Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 16: Global Pegfilgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 17: Global Pegfilgrastim Biosimilars Market, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 18: Global Pegfilgrastim Biosimilars Market, Sub-Segmentation Of Chemotherapy Treatment, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 19: Global Pegfilgrastim Biosimilars Market, Sub-Segmentation Of Transplantation, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 20: Global Pegfilgrastim Biosimilars Market, Sub-Segmentation Of Other Applications, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 21: Global Pegfilgrastim Biosimilars Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 22: Global Pegfilgrastim Biosimilars Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 23: Asia-Pacific, Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 24: Asia-Pacific, Pegfilgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 25: Asia-Pacific, Pegfilgrastim Biosimilars Market, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 26: China, Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 27: China, Pegfilgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 28: China, Pegfilgrastim Biosimilars Market, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 29: India, Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 30: India, Pegfilgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 31: India, Pegfilgrastim Biosimilars Market, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 32: Japan, Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 33: Japan, Pegfilgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 34: Japan, Pegfilgrastim Biosimilars Market, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 35: Australia, Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 36: Australia, Pegfilgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 37: Australia, Pegfilgrastim Biosimilars Market, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 38: Indonesia, Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 39: Indonesia, Pegfilgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 40: Indonesia, Pegfilgrastim Biosimilars Market, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 41: South Korea, Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 42: South Korea, Pegfilgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 43: South Korea, Pegfilgrastim Biosimilars Market, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 44: Taiwan, Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 45: Taiwan, Pegfilgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 46: Taiwan, Pegfilgrastim Biosimilars Market, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 47: South East Asia, Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 48: South East Asia, Pegfilgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 49: South East Asia, Pegfilgrastim Biosimilars Market, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 50: Western Europe, Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 51: Western Europe, Pegfilgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 52: Western Europe, Pegfilgrastim Biosimilars Market, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 53: UK, Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 54: UK, Pegfilgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 55: UK, Pegfilgrastim Biosimilars Market, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 56: Germany, Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 57: Germany, Pegfilgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 58: Germany, Pegfilgrastim Biosimilars Market, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 59: France, Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 60: France, Pegfilgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 61: France, Pegfilgrastim Biosimilars Market, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 62: Italy, Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 63: Italy, Pegfilgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 64: Italy, Pegfilgrastim Biosimilars Market, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 65: Spain, Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 66: Spain, Pegfilgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 67: Spain, Pegfilgrastim Biosimilars Market, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 68: Eastern Europe, Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 69: Eastern Europe, Pegfilgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 70: Eastern Europe, Pegfilgrastim Biosimilars Market, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 71: Russia, Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 72: Russia, Pegfilgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 73: Russia, Pegfilgrastim Biosimilars Market, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 74: North America, Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 75: North America, Pegfilgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 76: North America, Pegfilgrastim Biosimilars Market, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 77: USA, Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 78: USA, Pegfilgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 79: USA, Pegfilgrastim Biosimilars Market, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 80: Canada, Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 81: Canada, Pegfilgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 82: Canada, Pegfilgrastim Biosimilars Market, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 83: South America, Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 84: South America, Pegfilgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 85: South America, Pegfilgrastim Biosimilars Market, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 86: Brazil, Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 87: Brazil, Pegfilgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 88: Brazil, Pegfilgrastim Biosimilars Market, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 89: Middle East, Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 90: Middle East, Pegfilgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 91: Middle East, Pegfilgrastim Biosimilars Market, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 92: Africa, Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 93: Africa, Pegfilgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 94: Africa, Pegfilgrastim Biosimilars Market, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 95: Global Pegfilgrastim Biosimilars Key Competitor Estimated Market Shares, 2024, Percentage (%)
  • Table 96: Global Pegfilgrastim Biosimilars Market - Company Scoring Matrix
  • Table 97: Amgen Financial Performance
  • Table 98: Mylan N.V. Financial Performance
  • Table 99: Sandoz (a Novartis division) Financial Performance
  • Table 100: Teva Pharmaceutical Industries Ltd. Financial Performance
  • Table 101: Biocon Financial Performance
  • Table 102: Global Pegfilgrastim Biosimilars Market, Competitive Benchmarking (In USD Billions)
  • Table 103: Global Pegfilgrastim Biosimilars Market, Competitive Dashboard
  • Table 104: Global Pegfilgrastim Biosimilars Market Size Gain ($ Billion), 2025 – 2030 By Country
  • Table 105: Global, Pegfilgrastim Biosimilars Market Size Gain ($ Billion), Segmentation By Application, 2025 – 2030
  • Table 106: Global, Pegfilgrastim Biosimilars Market Size Gain ($ Billion), Segmentation By Distribution Channel, 2025 – 2030
  • Table 107: Global, Pegfilgrastim Biosimilars Market Size Gain ($ Billion), Segmentation By Route of Administration, 2025 – 2030

List Of Figures

    Figure 1: Global Pegfilgrastim Biosimilars Market, Overview Of Key Products - Product Examples
  • Figure 2: Global Pegfilgrastim Biosimilars Market Attractiveness, Factor-Wise Evaluation
  • Figure 3: Global Pegfilgrastim Biosimilars Market, Supply Chain Analysis
  • Figure 4: Global Pegfilgrastim Biosimilars Market, Major Raw Material Providers
  • Figure 5: Global Pegfilgrastim Biosimilars Market, Major Resource Providers
  • Figure 6: Global Pegfilgrastim Biosimilars Market, Major Manufacturers (Suppliers)
  • Figure 7: Global Pegfilgrastim Biosimilars Market, Major Distributors And Channel Partners
  • Figure 8: Global Pegfilgrastim Biosimilars Market, Key Technologies & Future Trends
  • Figure 9: Global Pegfilgrastim Biosimilars Market, Major Trends
  • Figure 10: Global Pegfilgrastim Biosimilars Market, Major End Users
  • Figure 11: Global Pegfilgrastim Biosimilars Market, PESTEL (Political, Economic, Social, Technology, Environmental and Legal) Analysis
  • Figure 12: Global Pegfilgrastim Biosimilars Historic Market Growth, 2020-2025, $ Billion
  • Figure 13: Global Pegfilgrastim Biosimilars Forecast Market Growth, 2025-2030F, 2035F, $ Billion
  • Figure 14: Global Pegfilgrastim Biosimilars Market - TAM, US$ Billion, 2025
  • Figure 15: Global Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 16: Global Pegfilgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 17: Global Pegfilgrastim Biosimilars Market, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 18: Global Pegfilgrastim Biosimilars Market, Sub-Segmentation Of Chemotherapy Treatment, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 19: Global Pegfilgrastim Biosimilars Market, Sub-Segmentation Of Transplantation, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 20: Global Pegfilgrastim Biosimilars Market, Sub-Segmentation Of Other Applications, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 21: Global Pegfilgrastim Biosimilars Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 22: Global Pegfilgrastim Biosimilars Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 23: Asia-Pacific, Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 24: Asia-Pacific, Pegfilgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 25: Asia-Pacific, Pegfilgrastim Biosimilars Market, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 26: China, Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 27: China, Pegfilgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 28: China, Pegfilgrastim Biosimilars Market, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 29: India, Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 30: India, Pegfilgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 31: India, Pegfilgrastim Biosimilars Market, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 32: Japan, Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 33: Japan, Pegfilgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 34: Japan, Pegfilgrastim Biosimilars Market, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 35: Australia, Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 36: Australia, Pegfilgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 37: Australia, Pegfilgrastim Biosimilars Market, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 38: Indonesia, Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 39: Indonesia, Pegfilgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 40: Indonesia, Pegfilgrastim Biosimilars Market, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 41: South Korea, Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 42: South Korea, Pegfilgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 43: South Korea, Pegfilgrastim Biosimilars Market, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 44: Taiwan, Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 45: Taiwan, Pegfilgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 46: Taiwan, Pegfilgrastim Biosimilars Market, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 47: South East Asia, Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 48: South East Asia, Pegfilgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 49: South East Asia, Pegfilgrastim Biosimilars Market, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 50: Western Europe, Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 51: Western Europe, Pegfilgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 52: Western Europe, Pegfilgrastim Biosimilars Market, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 53: UK, Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 54: UK, Pegfilgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 55: UK, Pegfilgrastim Biosimilars Market, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 56: Germany, Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 57: Germany, Pegfilgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 58: Germany, Pegfilgrastim Biosimilars Market, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 59: France, Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 60: France, Pegfilgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 61: France, Pegfilgrastim Biosimilars Market, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 62: Italy, Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 63: Italy, Pegfilgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 64: Italy, Pegfilgrastim Biosimilars Market, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 65: Spain, Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 66: Spain, Pegfilgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 67: Spain, Pegfilgrastim Biosimilars Market, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 68: Eastern Europe, Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 69: Eastern Europe, Pegfilgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 70: Eastern Europe, Pegfilgrastim Biosimilars Market, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 71: Russia, Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 72: Russia, Pegfilgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 73: Russia, Pegfilgrastim Biosimilars Market, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 74: North America, Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 75: North America, Pegfilgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 76: North America, Pegfilgrastim Biosimilars Market, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 77: USA, Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 78: USA, Pegfilgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 79: USA, Pegfilgrastim Biosimilars Market, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 80: Canada, Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 81: Canada, Pegfilgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 82: Canada, Pegfilgrastim Biosimilars Market, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 83: South America, Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 84: South America, Pegfilgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 85: South America, Pegfilgrastim Biosimilars Market, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 86: Brazil, Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 87: Brazil, Pegfilgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 88: Brazil, Pegfilgrastim Biosimilars Market, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 89: Middle East, Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 90: Middle East, Pegfilgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 91: Middle East, Pegfilgrastim Biosimilars Market, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 92: Africa, Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 93: Africa, Pegfilgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 94: Africa, Pegfilgrastim Biosimilars Market, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 95: Global Pegfilgrastim Biosimilars Key Competitor Estimated Market Shares, 2024, Percentage (%)
  • Figure 96: Global Pegfilgrastim Biosimilars Market - Company Scoring Matrix
  • Figure 97: Amgen Financial Performance
  • Figure 98: Mylan N.V. Financial Performance
  • Figure 99: Sandoz (a Novartis division) Financial Performance
  • Figure 100: Teva Pharmaceutical Industries Ltd. Financial Performance
  • Figure 101: Biocon Financial Performance
  • Figure 102: Global Pegfilgrastim Biosimilars Market, Competitive Benchmarking (In USD Billions)
  • Figure 103: Global Pegfilgrastim Biosimilars Market, Competitive Dashboard
  • Figure 104: Global Pegfilgrastim Biosimilars Market Size Gain ($ Billion), 2025 – 2030 By Country
  • Figure 105: Global, Pegfilgrastim Biosimilars Market Size Gain ($ Billion), Segmentation By Application, 2025 – 2030
  • Figure 106: Global, Pegfilgrastim Biosimilars Market Size Gain ($ Billion), Segmentation By Distribution Channel, 2025 – 2030
  • Figure 107: Global, Pegfilgrastim Biosimilars Market Size Gain ($ Billion), Segmentation By Route of Administration, 2025 – 2030

Advanced Therapy Medicinal Products Industry Poised for Rapid Expansion, Projected to Hit $104.43 Billion by 2029

Read More About Advanced Therapy Medicinal Products Industry Poised for Rapid Expansion, Projected to Hit $104.43 Billion by 2029

Global Insights: Androgen Deprivation Therapy Market Expected to Surpass $10.49 Billion by 2029

Read More About Global Insights: Androgen Deprivation Therapy Market Expected to Surpass $10.49 Billion by 2029

2025 Anti-CD20 Monoclonal Antibodies Market Outlook: Opportunities, Growth Trends, and Strategic Analysis

Read More About 2025 Anti-CD20 Monoclonal Antibodies Market Outlook: Opportunities, Growth Trends, and Strategic Analysis

Future Projections: Anti-D Immunoglobulin Market to Reach $3.34 Billion by 2029 at 6.6% CAGR

Read More About Future Projections: Anti-D Immunoglobulin Market to Reach $3.34 Billion by 2029 at 6.6% CAGR

Anti-Inflammatory Biologics Market Revenue Outlook: Strategic Insights and Forecast to 2029

Read More About Anti-Inflammatory Biologics Market Revenue Outlook: Strategic Insights and Forecast to 2029

CAGR of 10.8% Projected for Anti-Tumor Drugs Market From 2025 to 2029

Read More About CAGR of 10.8% Projected for Anti-Tumor Drugs Market From 2025 to 2029

Future Demand and Leading Companies Shaping the Asthma Disease Market to 2029

Read More About Future Demand and Leading Companies Shaping the Asthma Disease Market to 2029

Comprehensive Forecast: Asthma Therapeutics Market Share, Growth, and Opportunities Through 2029

Read More About Comprehensive Forecast: Asthma Therapeutics Market Share, Growth, and Opportunities Through 2029

Biosimilars Market Report 2026 - Global Outlook – By Type (Monoclonal Antibodies, Insulin, Erythropoietin, Granulocyte-Colony Stimulating Factor, Other Hormones), By Protein Type (Recombinant Non-glycosylated Proteins, R...

Oncology Biosimilars Market Report 2026 - Global Outlook – By Drug Type (Monoclonal Antibody, Immunomodulators, Hematopoietic Agents, Granulocyte Colony-Stimulating Factor (G-CSF) ), By Cancer Type (Breast Cancer, Colore...

Trastuzumab Biosimilars Market Report 2026 - Global Outlook – By Product (Ogivri, Herzuma, Ontruzant, Trazimera, Other Products), By Indication (Adjuvant Breast Cancer, Metastatic Breast Cancer, Metastatic Gastric Cancer...

Rituximab Biosimilars Market Report 2026 - Global Outlook – By Route Of Administration (Subcutaneous, Intravenous), By Application (Non-Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia, Rheumatoid Arthritis, Other Applic...

Biosimilar Hormones Market Report 2026 - Global Outlook – By Type (Teriparatide Biosimilars, Follitropin Alfa Biosimilars, Insulin Biosimilars, Somatropin Biosimilars, Other Types), By Application (Research & Biotechnolo...

Adalimumab, Infliximab and Etanercept Biosimilars Market Report 2026 - Global Outlook – By Product (Adalimumab Biosimilars, Infliximab Biosimilars, Cipleumab), By Distribution Channel (Hospital Pharmacies, Retail Pharmac...

Filgrastim Biosimilars Market - By Application (Oncology, Chronic and Autoimmune Diseases, Blood disorders, Growth hormone deficiency), By Distribution Channel (Hospital pharmacies, Retail pharmacies, Online pharmacies),...

Oral Biologics And Biosimilars Market - By Therapeutic Mechanism (Tumor Necrosis Factor-Alpha Inhibitors, Lymphocyte Modulators, Interleukin Inhibitors, GPCR (insulin, growth hormone, parathyroid hormone) Modulators, Imm...

Frequently Asked Questions

The Pegfilgrastim Biosimilars market was valued at $1.92 billion in 2025, increased to $2.04 billion in 2026, and is projected to reach $2.65 billion by 2030.

The global Pegfilgrastim Biosimilars market is expected to grow at a CAGR of 6.7% from 2026 to 2035 to reach $2.65 billion by 2035.

Some Key Players in the Pegfilgrastim Biosimilars market Include, Amgen, Mylan N.V., Sandoz (a Novartis division), Teva Pharmaceutical Industries Ltd., Biocon, Pfizer, Celltrion Healthcare, Coherus BioSciences, Gedeon Richter, Fresenius Kabi, Hetero Labs, Intas Pharmaceuticals, LG Chem, Merck KGaA, Zydus Cadila, Aurobindo Pharma, Apotex Inc., Dr. Reddy's Laboratories, Stada Arzneimittel AG, Shanghai Henlius Biotech, Alvotech, EirGenix, Kye Pharmaceuticals, CinnaGen, Boryung Pharmaceutical, Sinopharm .

Major trend in this market includes: High Quality Biosimilar For Providing Better Alternative. For further insights on this market. request a sample here

North America was the largest region in the pegfilgrastim biosimilars market in 2025. Middle East is expected to be the fastest growing region in the global pegfilgrastim biosimilars market share during the forecast period. The regions covered in the pegfilgrastim biosimilars market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Customer representative image Book your 30 minutes free consultation with our research experts
Contact Us